Benitec Ltd

Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases.

Their transformational technology, ddRNAi, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. Compared to traditional approaches to RNA intereference, ddRNAi is easier to deliver, safer to us, more targeted and more efficient.

Benitec has a pipeline of in-house and partnered drug development programs based on ddRNAI, including Hepatitis C and B, cancer-associated pain and drug-resistant lung cancer. Our Hepatitis C program is nearing clinical trials in 2013.

ddRNAi has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. The technology is available from Benitec under a variety of licence options.

Benitec Ltd headquartered in United States, North America, operates in the Biotechnology, Medical, Therapeutics, Genetics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $16.7B in funding across 140 round(s). With a team of 11-50 employees, Benitec Ltd is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Benitec Ltd, raised $29.5M. Discover more about their projects, partnerships, and impact on our platform.